Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
ConclusionsIn Chinese subjects, alirocumab 75, 150, and 300 mg was safe and well-tolerated. Pharmacokinetic/pharmacodynamic parameters, including clinically meaningful reductions in LDL-C and other lipids/lipoproteins, were consistent with data from Japanese and Western populations.Clinicaltrials.gov identifier: NCT02979015.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | China Health | Cholesterol | Heart | Japan Health | Statin Therapy | Study